Hancock Jaffe News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Chronic Venous Insufficiency typically refers to lower extremity edema, skin trophic changes, and discomfort secondary to venous hypertension....

Gainers Lixte Biotech Holdings (NASDAQ:LIXT) shares moved upwards by 16.45% to $3.75 during Tuesday’s after-market session. Today’s trading volume for this security ended up closing at 1.0 million shares, which is 100.31 percent of its average volume over the last 100 days. The company’s market cap stands at $51.2 million. Repro-Med Systems (NASDAQ:KRMD) shares moved upwards by 6.45% to $4.45. Trading volume for this security closed at 4.8K, accounting for 1.34% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $197.9 million. As ...

Provided by Accesswire Apr 23, 2021 4:40 PM UTC IRVINE, CA / ACCESSWIRE / April 23, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI's first-in-human VenoValve® study in Bogota, Colombia, presented one year data this past week at the Charing Cross International Symposium. The Charing Cross International Symposium is the longest-running vascular and endovascular global symposium in Europe and is attended by the wor...

Hancock Jaffe Laboratories, Inc.: Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium April 23, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI's first-in-human VenoValve® study in Bogota, Colombia, presented one year data this past week at the Charing Cross International Symposium. The Charing Cross International Symposium is the l...

Hancock Jaffe Laboratories, Inc.: First U.S. Patent Issues on Hancock Jaffe VenoValve / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the United States Patent and Trademark Office (USPTO) has issued the first patent covering the company's VenoValve. The patent is entitled Implantable Vein Frame and is U.S. patent number 10,959,841. The company recently announced that only twenty-eight (28) days after filing, the U.S. Food and Drug Administration (FDA) approved the company's Investigational Devic...